Repare Therapeutics expects cash to fund operations into mid-2026
PremiumThe FlyRepare Therapeutics expects cash to fund operations into mid-2026
1M ago
Repare Therapeutics reports Q2 EPS (82c), consensus (87c)
Premium
The Fly
Repare Therapeutics reports Q2 EPS (82c), consensus (87c)
1M ago
Repare Therapeutics management to meet virtually with Piper Sandler
Premium
The Fly
Repare Therapeutics management to meet virtually with Piper Sandler
2M ago
Repare Therapeutics reports Q1 EPS 30c, consensus 2c
PremiumThe FlyRepare Therapeutics reports Q1 EPS 30c, consensus 2c
5M ago
Repare Therapeutics, Debiopharm dose first patient in Module 4 of MYTHIC trial
Premium
The Fly
Repare Therapeutics, Debiopharm dose first patient in Module 4 of MYTHIC trial
5M ago
Repare Therapeutics Announces Board Changes and FD Disclosure
Premium
Company Announcements
Repare Therapeutics Announces Board Changes and FD Disclosure
5M ago
RPTX Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsRPTX Upcoming Earnings Report: What to Expect?
7M ago
Repare Therapeutics doses first patient in LIONS clinical trial
Premium
The Fly
Repare Therapeutics doses first patient in LIONS clinical trial
7M ago
Repare Therapeutics price target lowered to $10 from $25 at H.C. Wainwright
Premium
The Fly
Repare Therapeutics price target lowered to $10 from $25 at H.C. Wainwright
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100